An interview with Grigorios Gerotziafas
ISTH 2018 – Grigorios...
ICTHIC 2018
Rapping about new anticoagulants for CAT at ICTHIC 2018
Rapping about new anticoagulants for CAT at ICTHIC 2018 Cancer patients are four or five times as likely to develop...
Nicola Mutch at ICTHIC 2018
We met with Nicola Mutch, president elect of the ISTH SCC, during the 9th ICTHIC in Bergamo. She explains where her...
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological...
Arterial thromboembolism can also be the first clinical manifestation of a neoplasm
Several studies showed that venous thrombosis can be the first clinical manifestation of an occult neoplasm. For this...
Are new anticoagulants a safe and reasonable alternative to low molecular weight heparins?
Dr. Buller and Dr. Noble comment on their DOACs face-off that took place during the 9th ICTHIC...
The management of cancer patients with hemostatic disorders (thrombosis and/or bleeding) faces many clinical challenges
The management of cancer patients with hemostatic disorders (thrombosis and/or bleeding) faces many clinical...
Hemostatic proteins and cancer biology: news from the research groups
The expression of hemostatic proteins in cancer and their role in cancer biology is one of the themes that were...
The conundrum of anti-angiogenesis in cancer
“Anti-angiogenesis in cancer is something of a conundrum where the unexpected is to be expected.”...
Exploring mechanisms and new targets, preventing thrombosis and treating VTE
The search for a deeper understanding of the molecular interactions that occur between thrombosis and cancer is...